Trials / Completed
CompletedNCT05493995
A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.
A Multicenter Study of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as First-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer: PAAG.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Penpulimab | Penpulimab 200 mg administered intravenously every 3 weeks. |
| DRUG | Anlotinib | 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle. |
| DRUG | Nab paclitaxel | 125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle. |
| DRUG | Gemcitabine | 1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle. |
Timeline
- Start date
- 2022-07-21
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2022-08-09
- Last updated
- 2024-05-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05493995. Inclusion in this directory is not an endorsement.